Harbour BioMed partners Otsuka on new T-cell therapy
Pharmaceutical Technology
JUNE 23, 2025
June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Credit: luchschenF /Shutterstock.
Let's personalize your content